CV Sciences, Inc. (OTCMKTS:CVSI) is currently trading at one of its lowest price points in about a year. The decline that has taken the stock to its current lows began unfolding in mid-September.
By late September, CVSI had lost so much ground that the stock was trading below $1.60. However, it again began moving up and in early October the stock had climbed back up enough to flirt with $2.60. From that level, CVSI retreated and by mid-October it was doing rounds at about $1.85. The stock began climbing back up again and toward late October it was trading well above $2. But in late October until now it has begun pulling back again, closing down in three of the last five trading sessions.
Looking at the charts, you cannot dispute that CVSI has demonstrated a pattern that investors can take advantage of to profit from the stock in short-terms. After rallying, CVSI tends to pull back, thereby allowing investors who may have missed its previous bull run to get on board before it begins another flight. Therefore, you shouldn’t be surprised if CVSI sharply reverses course and begins trending up from current levels.
CVSI is a hemp CBD company that makes products for both consumer and therapeutics markets. The company operates production facilities that follow good manufacturing practices. Its PlusCBD Oil product has been noted as the top-selling hemp CBD brand.
CVSI has cheered USDA’s establishment of the US domestic hemp production program. According to CVSI, the program will provide consistent regulatory framework that supports responsible hemp production in the US.
Beyond the historic price actions that paint a clear up and down pattern in the stock that investors can leverage to profit from CVSI, there are still more catalysts to power CVSI to greater highs from current level.
In October, CVSI made several announcements that should be positive for the stock in November.
CVSI equips its board with strategically valuable directors
CVSI last month added to new directors to its board. These are Dr. Paul Blake, who joined the CVSI board on October 21, and Beth Altman, who joined the CVSI board on October 24.
Blake is currently the chief medical officer at Heron Therapeutics, commercial-stage biotechnology company that focuses on pain treatment for cancer patients and others. Prior to joining Heron, Blake held executive roles at various other pharmaceutical companies, including BioDelivery Sciences International and Oxford BioMedica. To CVSI’s table, Blake brings deep expertise in drug development.
“His [Blake ‘s] decades of experience leading pharmaceutical companies will be invaluable to us as we continue to strengthen our industry leadership position in CBD consumer products and drug development,” commented Joseph Dowling, CEO of CVSI.
Altman, CVSI’s other new board addition, is also expected to be strategically valuable to the company. Altman has worked as global auditing and consultancy giant KMPG since 1993. Therefore, she brings more than 25 years of experience as a finance executive to CVSI.
“Beth is a tremendous asset to CV Sciences as we further expand our Company and fuel our future growth,” commented Joseph Dowling, CEO of CVSI.
CVSI extends its product distribution network to boost sales
CVSI inked two product distribution agreements in October. The first deal was with American supermarket chain Harris Teeter. The agreement with Harris Teeter paves the way for CVSI to sell its hemp cannabidiol (CBD) products at 150 Harris Teeter stores across several states in the United States.
CVSI has also expanded its CBD products distribution arrangement with The Vitamin Shoppe. The expanded agreement gives CVSI access to 132 more The Vitamin Shoppe stores. So in total CVSI will be able to sell its hemp CBD products at 515 The Vitamin Shoppe locations in the United States and Puerto Rico.
CVSI’s moves to expand its product distribution are notable as they come at a time when demand for hemp CBD products is increasing. A new report from market intelligence firm Brightfield Group shows the hemp CBD market in the US is expanding at an unprecedented rate. Brightfield predicts the hemp CBD market in the US will grow to $23.7 billion by 2023. This is the opportunity CVSI is pursuing and it hopes a broader product distribution network will allow it to take full advantage of the opportunity.
CVSI is considered by many to be the premier CBD stock trading on the OTC Market at this time. With all the deals the company is signing with major retailers, it’s only a matter of time before CVSI graduates to the NASDAQ. That is why you don’t want to miss out on the bounce back in the stock. And at the current price, CVSI looks to be a discount entry opportunity.
We will be updating our subscribers as soon as we know more. For the latest updates on OTCMKTS:CVSI, sign up below!
Disclosure: We have no position in OTCMKTS:CVSI and have not been compensated for this article.
Can Isodiol International Inc (CNSX:ISOL)(OTCMKTS:ISOLF) Break Out From Here?
Investors have jumped on Isodiol International Inc (CNSX:ISOL)(OTCMKTS:ISOLF) stock this month. The stock gained 62% on January 21, marking its best day so far in 2020. The stock has already gained 106% year-to-date. But do not think even for a minute that investors have warmed up to Isodiol stock for nothing. This is a stock with tremendous potential and at this point, the stock is just showing early signs of what is going to be a big breakout.
In case you are wondering why investors have started jostling for a piece of Isodiol early on in the year, this report answers that question and more. But before we delve into the details, it is important to first understand the company we’re discussing here.
About Isodiol International
Isodiol International is a Canadian company that has specialized in the making of pharmaceutical and consumer products derived from hemp. It makes CBD products derived from hemp grown and processed in the United States. Though Isodiol’s operations are currently concentrated in North America, the company has big expansion dreams. It has set its sights on expanding into Latin America, Asia, and Europe.
What exactly is drawing investors to Isodiol stock and why does it stand out as a good pick in the hemp/cannabis stock universe in 2020? The simple answer is that investors are beginning to realize Isodiol’s bright prospects as a CBD products company.
Isodiol bidding for…
New Age Beverage (NASDAQ:NBEV) Solid Fundamentals Amidst Price Slump
New Age Beverage (NASDAQ:NBEV) has taken a significant beating since the start of the year. A 60% plus slide attests to a stock under immense pressure. Amidst the underperformance in the stock market, the company has continued to do exceedingly well when it comes to core business execution and operation efficiency.
New Age Beverage Catalysts And Price Analysis
Triple-digit revenue growth is one of the developments that continues to affirm the company’s long-term prospects. The company also remains well-positioned to generate bottom-line growth backed by robust retail channels in the U.S as well as expansion in Asia. Integration of Morinda operations in China is another development likely to continue strengthening the company’s bottom line going forward.
A spike in implied volatility in the options market is the latest development that signals a potential turnaround in the direction of trade. Huge implied volatility indicates that trade is developing. What is clear is that the stock has taken a significant hit and may be due for a correction higher, given the improving fundamentals.
Increased activity around the $2.50 Put options could signal a potential change in the direction of trade. After the recent slide lower, the stock needs to rise and find support above the $2.40 resistance level. A rally past the $2.40 level should reaffirm New Age Beverages bounce back prospects.
Above the crucial resistance level, the stock should be on its way to the…
Charlotte’s Web Stock (TSE:CWEB) (OTCMKTS:CWBHF) Poised For Breakout And Here’s Why
Charlotte’s Web Stock (TSE:CWEB) (OTCMKTS:CWBHF) is currently at one of its lowest price levels in about five months. That is the result of a selloff that kicked off toward late September after the stock reached one of its highest watermarks at $23 in August.
You cannot rule out profit-taking as having contributed to the decline that has brought the stock to its current lows considering the stock pulled up from one of its lowest levels this year in July before the August breakout. A repeat of the August bull run that powered CWBHF to one of its highest price levels this year seems to be in the offing.
Firstly, after a string of declines for much of last week and early this week, CWBHF has begun showing signs of a comeback. The stock closed the last session (November 5), up. Now the stock has found immediate support at $10.9 from where it looks set for a powerful breakout as happened in March, June, and July.
In March, for instance, CWBHF bolted from a low of $13 on March 8 to reach its one-year peak of $25 in a space of fewer than 30 days on April 4. Profit-taking kicked off after that and the stock fell to around $10 in mid-June, from where it began rising again, topping $18.5 in early July. Investors again took profit and toward late July the stock was back down at around $13.5.…